Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which suppress the development of new tumor vasculature, VDAs target established tumor vasculatur...

Descripción completa

Detalles Bibliográficos
Autores principales: Grisham, Rachel, Ky, Bonnie, Tewari, Krishnansu S., Chaplin, David J., Walker, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756341/
https://www.ncbi.nlm.nih.gov/pubmed/29318022
http://dx.doi.org/10.1186/s40661-017-0058-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756341/
https://www.ncbi.nlm.nih.gov/pubmed/29318022
http://dx.doi.org/10.1186/s40661-017-0058-5

Ejemplares similares